Skip to content

Home
About Us
Oncology
Preclinical Services
Shareholders
News & Resources
Contact Us
English

Menu

Home
About Us
Oncology
Preclinical Services
Shareholders
News & Resources
Contact Us
English

Announcements

Investors

Financial
Reports

Analyst
Reports

Press
Releases

ASX
Announcements

Investors

Financial Reports

Analyst Reports

Announcements

Shareholders

Invitrocue announces acquisition of Welala to create life science leadership in Thailand and Asean

September 23, 2024

Invitrocue’s Onco-PDO test is Singapore’s and world’s first validated and approved Clinical Cancer Drug Screening service for Personalised Oncology

March 5, 2024

Operational Updates – February 2024

February 7, 2024

Operational Updates – October 2023

November 9, 2023

Thailand FDA grants approval for commercial use of MyTruHealth and MyTruAge DNA Methylation Test Kit

August 18, 2023

Singapore’s Ministry of Health grant license approval for commercial use for Onco-PDO™ – Personalized Cancer Drug Screening

July 13, 2023

International MOU inked between chemistry and biomedical talents from Hong Kong, Singapore and Europe for late-stage cancer research enhancement.

July 27, 2022

Operational Updates and Management Accounts

February 18, 2022

Quarterly Updates – March 2021

May 3, 2021

Delisting from ASX Official List

February 26, 2021

Appendix 4C – quarterly

February 1, 2021

4C Commentaries and Management Updates

May 1, 2020

Appendix 4C – quarterly

April 30, 2020

Board Changes – 3 Mar 2020

March 3, 2020

Invitrocue enters MOU to establish a Joint Venture for Brazilian and Latin American Market

February 11, 2020

Appendix 4C – Commentaries & Management Updates

February 6, 2020

Quarterly Appendix 4C – December 2019

January 1, 2020

Cleansing prospectus

December 17, 2019

Change of Director's Interest Notice – Dr Andreas Lindner

December 17, 2019

Proposed issue of Securities – IVQ

December 17, 2019

Significant investment and joint venture with a fund

December 9, 2019

Results of Annual General Meeting – 2019

November 28, 2019

Quarterly Appendix 4C

November 1, 2019

Notice of Annual General Meeting – 2019

October 30, 2019

Appendix 4E – 2019

October 21, 2019

Invitrocue Establishes Hong Kong Laboratory

October 21, 2019

Invitrocue Clinical Studies underway in Germany

October 21, 2019

Annual Report – 2019

October 3, 2019

Appendix 3B – September 2019

September 9, 2019

Collaboration with National University Hospital Singapore

September 9, 2019

Quarterly Appendix 4C and Business updates

September 9, 2019

Invitrocue Appoints Global Insurance Advisor

May 6, 2019

Quarterly Appendix 4C and Business updates

April 30, 2019

Appendix 3B – March 2019

April 30, 2019

Cleansing Statement – April 2019

April 30, 2019

Appendix 3Z – Jamie Khoo – March 2019

March 15, 2019

Appendix 3X – Kit Wei Lui – March 2019

March 15, 2019

Board Changes – March 2019

March 12, 2019

Cleansing Statement – March 2019

March 6, 2019

Appendix 3B – March 2019

March 6, 2019

Appendix 4D – Half Yearly Report and Accounts

March 4, 2019

Invitrocue Appoints Professor Arial Zeng Yi as Patient Derived Organoid Consultant

February 19, 2019

Invitrocue creates Joint Venture with A*STAR scientist Dr. Chen Qingfeng

February 11, 2019

Quarterly Appendix 4C and Business updates

February 1, 2019

IVQ technology development agreement with SIBCB on breast cancer.

January 23, 2019

Invitrocue roll-out of Onco-PDO services in Germany

January 21, 2019

Invitrocue Appoints Renowned Oncology Researcher Professor Jesús García-Foncillas as Clinical Advisor

January 15, 2019

Expiry of unlisted options – Jan 2019

January 15, 2019

Final Director's Interest Notice

January 11, 2019

Invitrocue Appoints Professor Masakazu Toi as Clinical Advisor

January 11, 2019

Invitrocue announced Board Changes

January 9, 2019

Change of Director's Interest Notice

December 27, 2018

Change of Director's Interest Notice

December 21, 2018

Change of Director's Interest Notice

December 19, 2018

Change of Director's Interest Notice

December 18, 2018

Change of Director's Interest Notice

December 18, 2018

Change of Director's Interest Notice

December 18, 2018

Appendix 3B – December 2018

December 17, 2018

Cleansing Statement – December 2018

December 17, 2018

Results of Annual General Meeting

November 30, 2018

Dr Lindner as Europe CEO and Prof Waugh as Senior Advisor

November 19, 2018

Quarterly Appendix 4C and Business updates

November 1, 2018

Notice of Annual General Meeting/Proxy Form

October 30, 2018

Initial Director's Interest Notice – Dr Gary W Pace

October 23, 2018

Appointment of Dr. Gary W. Pace as director

October 23, 2018

Assoc Prof Iyer as Chair of IVQ Medical Advisory Board

October 22, 2018

Annual Report to shareholders

September 28, 2018

Appendix 4G

September 28, 2018

Notice of Ceasing to be a Substantial Holder

September 10, 2018

Business updates

September 4, 2018

Preliminary Final Report

August 31, 2018

Change in substantial holding

August 28, 2018

Appendix 4C – quarterly

July 31, 2018

Expiry of Unlisted Warrants

July 17, 2018

Expiry of Unlisted Warrants

July 2, 2018

Cleansing statement

June 28, 2018

Appendix 3B

June 28, 2018

Proposed issue of securities

June 26, 2018

Change in substantial holding

May 25, 2018

Appendix 4C – quarterly

April 30, 2018

Appendix 4G

April 27, 2018

IVQ launches Personalised Cancer Screening Service Onco-PDO

April 13, 2018

Half Yearly Report and Accounts

February 28, 2018

Grant from Northern Ireland to commercialize Onco-PDO

February 26, 2018

Investor Presentation

February 23, 2018

Change of Director's Interest Notice – Jamie Khoo

February 20, 2018

Change of Director's Interest Notice – Steven Fang

February 20, 2018

Change of Director's Interest Notice

February 14, 2018

Change of Director's Interest Notice

February 14, 2018

Change of Director's Interest Notice

February 14, 2018

Change of Director's Interest Notice

February 14, 2018

Change of Director's Interest Notice

February 14, 2018

Initial Director's Interest Notice

February 12, 2018

Appendix 3B

February 9, 2018

Appointment of non-executive director

February 7, 2018

Appendix 4C & quarterly business update

January 31, 2018

Appendix 3B

January 29, 2018

IVQ successfully grows liver cancer organoids

January 18, 2018

Escrow Release

January 15, 2018

Cleansing Statement

December 8, 2017

Appendix 3B

December 8, 2017

Proposed Issue of Securities

December 7, 2017

Results of Annual General Meeting

November 30, 2017

2017 AGM Presentation

November 30, 2017

Cleansing Statement

November 13, 2017

Appendix 3B

November 13, 2017

Proposed issue of securities

November 10, 2017

Quarterly Business Update and Investor Calls

October 31, 2017

Appendix 4C – Quarterly Report

October 30, 2017

Notice of Annual General Meeting/Proxy Form

October 30, 2017

Annual Report to Shareholders

September 29, 2017

Appointments to the Management Team

September 28, 2017

Preliminary Final Report

August 31, 2017

IVQ receives award from Singapore government IP office

August 29, 2017

Investor Presentation

August 29, 2017

Appendix 4C – Quarterly Report and Business Update

July 31, 2017

Launch of New Joint Innovation Laboratory to Advance Personalised Medicine for Cancer Treatment

July 24, 2017

Invitrocue to work with Garvan Institute to Progress Personalised Real-time Screening of Cancer Drugs

July 3, 2017

Cleansing Statement

June 30, 2017

Appendix 3B – New Issue Announcement

June 30, 2017

Proposed Issue of Securities

June 29, 2017

Corporate Governance Statement

May 26, 2017

Invitrocue Expands Into In-Vitro Skin and Wound Healing Assays

May 22, 2017

Response to ASX Appendix 4C Query

May 11, 2017

Appendix 4C – Quarterly Report

April 28, 2017

Appendix 4D – Half Yearly Report and Accounts

February 28, 2017

Invitrocue Signs Research Collaboration Agreement with the Garvan Institute of Medical Research

February 23, 2017

Appendix 4C – Quarterly Report

January 30, 2017

Escrow Release

January 3, 2017

Results of Annual General Meeting 2016

November 30, 2016

Invitrocue Appoints DasGupta Ramanuj, Ph.D as Senior Scientific Director

November 24, 2016

Appendix 4C – Quarterly Report

October 31, 2016

Annual General Meeting 2016

October 28, 2016

Invitrocue Signs Research Collaboration Agreement with Genome Institute of Singapore for Colorectal Cancer Organoids

October 24, 2016

Annual Report For The Period Ended 30 June 2016

September 30, 2016

Addendum To Appendix 4E

September 8, 2016

InvitroCue Awarded A*STAR Tender

September 6, 2016

Preliminary Final Report

August 31, 2016

Appendix 3B – New Issue Announcement

August 30, 2016

InvitroCue Signs Strategic Partnership Agreement With QIAGEN Suzhou

August 22, 2016

Escrow Release

August 16, 2016

InvitroCue Announces New Program Focused on Hepatitis B Virus

July 28, 2016

Appendix 4C – Quarterly Report

July 28, 2016

Investment Fact Sheet July 2016

July 11, 2016

InvitroCue Commences Pancreatic Toxicity Assay Development

July 11, 2016

Notification of Change of Auditor

July 7, 2016

Investor Presentation (Mandarin)

June 14, 2016

Investor Presentation 16 May 2016

May 16, 2016

InvitroCue Announces Malaria Initiative

May 16, 2016

InvitroCue Expands 3D Cell-based Platform for Oncology

May 12, 2016

Appendix 4C – Quarterly Report

April 27, 2016

InvitroCue and SciKon Innovation Forge an Alliance to Create the Future of Perfused Human Liver Tissue

April 8, 2016

InvitroCue Launches Cellacyl: Proprietary Acyl Glucuronide Detection Assay

April 8, 2016

New Issue Announcement

March 30, 2016

Initial Director's Interest Notice

March 24, 2016

New Issue Announcement

March 23, 2016

Becoming a Substantial Holder – Steven Fang

March 15, 2016

Agreement with London School of Hygiene & Tropical Medicine

March 9, 2016

Novel 3D in vitro Techniques for Modeling leishmaniasis

March 9, 2016

Operations Update

March 8, 2016

InvitroCue Expands Cell-based Lab in Suzhou to Meet Client’s Increase China Focus

March 5, 2016

Half Yearly Report

February 29, 2016

Investor Presentation

February 15, 2016

Operations Update

February 8, 2016

Becoming a Substantial Holder – Clearbridge Accelerator

February 2, 2016

ImageIQ And InvitroCue Forge Partnership To Advance Quantitative Image Analysis For Preclinical Researchers In Asia

February 1, 2016

NCCS And InvitroCue To Develop Quantitative Cancer Imaging And Radiomics Applications For Treatment Of Liver Cancer Patients

January 28, 2016

Market Release: Reinstatement To Official Quotation

January 22, 2016

InvitroCue and Swiss InSphero MOU Signing Ceremony

April 8, 2015

GET IN TOUCH

51 Science Park Road, #01-11/13 The Aries, Singapore Science Park II Singapore 117586

GENERAL / PHARMACOLOGY ENQUIRIES:

+65 6460 0497
contact@invitrocue.com

ONCO-PDO ENQUIRIES:

+65 6819 0181
onco-pdo@invitrocue.com

SAC - SINGLAS Accredited Laboratory

SERVICES

Home
About Us
Oncology
Preclinical Services
Investors
News & Resources
Contact Us

Icon-twitter-x Facebook-f Linkedin-in Youtube

© Copyright 2025 Invitrocue. All rights reserved
Impressum | Privacy Policy | Cookies Policy | Cookie Settings